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Background: Sentinel node biopsy (SNB) is a gold standard in staging of early breast cancer.
Nowadays, routinemapping of lymphatic tract is based on two tracers: human albuminwith
radioactive technetium, with or without blue dye. Recent years have seen a search for new
tracers to examine sentinel node as well as lymphatic network. One of them is indocyanine
green (ICG) visible in infrared light.
Aim: The aim of this study is to evaluate clinical usage of ICG in comparison with standard
tracer, i.e. nanocoll, in SNB of breast cancer patients.
Materials and methods: In the 1st Department of Surgical Oncology and General Surgery,
Greater Poland Cancer Centre, Poznan´, 13 female breast cancer patients have benn operated
since September 2010. All these patients had sentinel node biopsy with nanocoll (human
albumin with radioactive technetium), and with indocyanine green. The feasibility of this
new method was assessed in comparison with the standard nanocoll.
Results: A lymphatic network between the place of injection of ICG and sentinel node wasseen in infrared light. An area where a sentinel node was possibly located was conﬁrmed
by gamma probe. Sensitivity of this method was 100%.
Conclusion: SNB using ICG is a new, promising diagnostics technique. This procedure is not
without drawbacks; nevertheless it opens new horizons in lymphatic network diagnostics.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.1. Background
Sentinel node biopsy (SNB) is a standard procedure in the
staging of early breast cancer. On the one hand, it is an easy
and safe way of providing information concerning the stag-
ing of a neoplastic disease and, on the other hand, it gives
most patients a possibility to have the lymphatic system of
the armpit spared.
∗ Corresponding author. Fax: +48 618850601.
E-mail address: surgoncolclub@gmail.com (K. Polom).
1507-1367/$ – see front matter © 2011 Greater Poland Cancer Centre, Poland
doi:10.1016/j.rpor.2011.02.005z.o.o. All rights reserved.
As regards negative results of the SNB, randomised multi-
centre clinical research proved the absence of a signiﬁcant
difference in local relapses and survival rate between patients
after resection and those with saved lymphatic system of
the armpit.1–3 The SNB provides beneﬁts of much smaller
incidence of complications and traumas as well as a better
quality of life in comparison with axillary lymphadenectomy.
At present, the standard procedure used in mapping lymph
vessels and sentinel lymph node involves the application of
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Fig. 1 – Place of injection of ICG intradermally above the
10min after the administration of ICG in all patients, the PDE
camera visualised the lymph ducts channels from the place of
administration of the tracer with the lymphatic system of the
armpit. In the place of atrophy of the lymph duct passage toreports of practical oncology an
racers based on albuminmarkedwith radioactive technetium
n combination with or without blue dye. Either technique has
ts advantages anddisadvantages. Originally, Guliano in breast
ancer, just like Morton in skin melanoma, used blue dye to
ocate the sentinel node.4,5 Later, Krag et al. used technetium
ulphur colloid, which enabled transcutaneous identiﬁcation
f the sentinel node.6 At present some centres use a radio-
olloid by itself without blue dye. In recent years, there has
een a search for an alternative method of visualisation of
he lymph vessels and sentinel node. Indocyanine green is
promising tracer which, after being administered intrader-
ally, ﬂows to the sentinel node and is visible in infrared light
lso through the skin. The application of the method is at the
tage of clinical research.
. Aim
he aimof the studywas to evaluate the usefulness of the new
ethod of sentinel lymph node mapping in comparison with
he radioactive technetium nanocolloid, which is a routinely
sed tracer.
. Materials and methods
ince September 2010, 13 consecutive women with diagnosed
reast cancer have undergone surgery in the 1st Department
f Surgical Oncology and General Surgery, Greater Poland Can-
er Centre, Poznan´. The group of patients had an early breast
ancer. Two of them had DCIS (ductal carcinoma in situ), 11
ad invasive cancers (2 cases of T1a, 5 cases of T1b, 4 cases
f T1c). In two cases, (both T1c) additional lymphadenectomy
as done following intraoperative pathological examination
f sentinel node because of metastases. The age of these
atients ranged between 41 and 69.
A new system of sentinel node location was implemented
n the patients. In order to visualise the sentinel lymph
ode, one day before the surgery the patients underwent
routine intradermal injection of radioactive technetium
anocolloid above the breast tumour. In the case of micro-
alciﬁcations scattered over the whole breast, the tracer was
dministered periareolarly from four needle injections. The
atients underwent lymphoscintigraphy. Immediately before
he surgery, indocyanine green (ICG) (concentration 5mg/ml,
olume 1–2ml) was also administered intradermally above
he tumour, or periareolarly in the case of microcalciﬁca-
ions scattered over the whole breast. Then, after 5–10min
ollowing the ICG injection, the lymph channels connecting
he place of administration with the lymphatic system were
isualised as along with the sentinel lymph node itself by
eans of a PDE (Photodynamic Eye) camera from Hamamatsu
hotonics K.K., Hamamatsu, Japan (Fig. 1). The ﬂuorescence
henomenon was used, which consists in the emission of
ight of appropriate wavelength from the substance which
bsorbs light of a different wavelength. The PDE camera emits
nfrared light with the wavelength of 760–805nm and ICG
xposed to the activity of that sends light radiation with the
avelength of about 820–830nm. The sent light and emitted
ight are called excitation light (LED) and ﬂuorescence light
espectively. The image was seen in infrared light emittedbreast cancer with two lymphatic channels passing to one
sentinel node.
by the camera. CCD (charged coupled device) is a device that
usually consists of three main components: an NIR (near-
infrared) sensitive image intensiﬁer, 16-bit dynamic-range
frame transfer CCD camera, and light emitting diodes (LED).
In comparison with the IC-View camera; Pulsion Medical
Systems, Munich, Germany, which we used previously, the
new system has more LEDs, which enables much better
quality of obtained image and improved sensitivity of the
examination. In each case, the ICG intercepted by the sentinel
node was conﬁrmed by means of a gamma probe of the
camera routinely used for detection of gamma radiation
transcutaneously during the SNB (Fig. 2), after opening the
wound and once more after sentinel node resection.
4. ResultsFig. 2 – Lymphatic channels after ICG injection ending in
the sentinel node-conﬁrmed with the gamma probe.
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Fig. 3 – Sentinel node stained with ICG after skin incision
and tissue dissection.
deeper structures of the armpit, including the sentinel lymph
node was suspected. The area was checked with a gamma
camera and in all cases the place transcutaneously showed
radiation captured from the sentinel node. After making an
incision in the skin and dissection of tissues, the sentinel node
with intense ICG capture was visualised in the PDE camera
(Fig. 3). In each case the node showed captured radiation in
the gamma camera. In 5 cases green colour of the node was
seen without camera (Fig. 4). The sensitivity of the method in
the abovementioned group was calculated at 100%. No side
effects of the procedure were observed.
5. Discussion
ICG is a non-toxic substance, which has been used in oph-
thalmology, transplantology or diagnostics and surgery of the
alimentary tract for many years.7–9 It is characterised by short
half-life in the organism and a strong tendency to compound
with serum proteins, especially with 1 lipoprotein. After
being injected and compounding with serum proteins, ICG
easily moves along the lymph ducts to nodal stations. Thus, it
is possible to visualise not only the place of administration of
the dye and the lymph duct, but also and above all the sentinel
lymph node.10
Table 1 – ICG and SNB in patients with breast cancer.
Number
of
patients
Type and dose of ICG Inject
Kitai et al.11 18 ICG, 5ml (25mg) Subcutaneous i
Tagaya et al.13 25 ICG, 1ml (5mg) Subdermally in
Murawa et al.14 30 ICG, 5mg, 10mg, 15mg Intradermal in
Troyan et al.15 6 ICG:HAS, 1.6ml (12.5g) Four deep perit
and four subcu
periotumoural
Hirche et al.16 43 ICG, average 11mg Subareolar regi
Hojo et al.17 141 Combination of 1% blue
dye 2ml+ ICG 2ml
Skin overlying t
subareolar regioFig. 4 – Sentinel node with ICG-view without camera-green
colour of the node.
Since 2005, when Kitai et al. ﬁrst suggested the applica-
tion of indocyanine green for mapping the lymph channels
and sentinel lymph node in breast cancer, the interest in
the new technique has increased considerably and studies
on the application of the method in marking the sentinel
node in other cancers have been done.11 Throughout the
detection process, it is necessary to use equipment with
an infrared emitting camera and indocyanine green show-
ing emission of light. In published articles, the tracer was
administered intradermally or subcutaneously and then after
5–10min the lymph vessel, and sentinel lymph node were
visualised. Until now, there have been no decisions concern-
ing the dose and, according to Sevick-Muraca, it is sufﬁcient
to apply ICG in concentration of 10–100g/ml up to 25mg/ml,
as suggested by Kitai et al.11,12 Another important problem
is the necessity to switch off the light in order to visualise
the ICG-dyed lymphatic system. Owing to the new equipment
from Hamamatsu, it is possible to keep the light on in the
operating theatre, except for intense surgical lightening that
needs to be switched off. When older generation cameras
were used, a complete darknesswas required during a surgery,
which resulted in many technical problems and considerably
ion site Positive
sentinel
lymph node
Metastatic
involvement of
SLN detected (%)
False
negative
(%)
n areola 17/18 (94%) 6/6 (100%) 0/11 (0)
areola 25/25 (100%) 8/8 (100%) 0/17 (0)
periareolar region 29/30 (97%) 19/21 (90%) 2/21 (10%)
umoural injection
taneous
injection
5/6 (83%) 3/9 (33%) –
on 42/43 (94.4%) 17/18 (94.4%) 1/43 (5.6%)
he tumour and
n
140/141 (99.3%) 5/31 (16.1%) –
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xtended the surgery time. Until now, we have had only a few
ublications describing the problemof SNB detectionwith ICG
n breast cancer (Table 1).
Currently used radioactive tracers are safe and emit
nsigniﬁcant amounts of radiation, but the application of ICG
liminates the problem completely. Another beneﬁt arising
rom the use of ICG is the safety of application.18 At present,
he risk of an anaphylactic reaction has been estimated at
.05% and side effects have only been observed with doses
onsiderably exceeding those recommended by the FDA (Food
nd Drug Administration).19 Such tracers as isosulfan dye in
NBhavebeen reported to cause anaphylaxis at a rate between
.7% and 1.1%, whereas the rate for patent blue was 0.4%.20–23
nother important argument supporting the application of
CG is real-time visualisation of not only the sentinel lymph
ode but also the whole lymph vessel during the surgery.
he time necessary to prepare the substance and the delay
etween the injection and visualisation of the lymph vessel
re also worth mentioning. For ICG, it is 15min and the whole
rocedure is performed perioperationally, while it takes up to
9h to prepare the radiocolloid, if the radiopharmaceutical is
dministered one day before the surgery. The inconvenience
f applying ICG in the SNB is that it requires the light to be
witched off. In recognising the problem, efforts by Troyan
t al. have resulted in development of the FLARETM imaging
ystem which offers a possibility to view surgical anatomy
ith two independent channels of NIR ﬂuorescence.15 How-
ver, it is necessary to mention the enormous cost of the
ppliance, which exceeds 120,000 dollars. Another challenge
s the depth at which ICG detection is possible. At present, the
imit is 1 cm of the tissue, which makes detection of deeper
ymph nodes impossible. The application of ICG in combina-
ion with other substances may improve the parameter. An
ppropriate length of training to become familiarwith the new
echnique is also necessary. At present, for a standard SNB it
s necessary to perform 20 biopsies on one’s own.24
SNB with the application of indocyanine green is a new
romising diagnostic technique. It is not free from disadvan-
ages. However, it opens a completely newscope in diagnostics
f the lymphatic system.
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